TY  - JOUR

T1  - Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

JO  - Trials

UR  - http://eprints.whiterose.ac.uk/93786/

PY  - 2015/12/16

AU  - Yardley DA

AU  - Brufsky A

AU  - Coleman RE

AU  - Conte PF

AU  - Cortes J

AU  - Glück S

AU  - Nabholtz J-MA

AU  - O’Shaughnessy J

AU  - Beck RM

AU  - Ko A

AU  - Renschler MF et al

ED  - 

DO  - DOI: 10.1186/s13063-015-1101-7

VL  - 16

Y2  - 2025/10/10

ER  -